INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary ImmunityBio to Present at the 38th Annual J.P. Morgan Healthcare Conference
Company Chairman and CEO to Present Clinical Status Report on QUILT Cancer Breakthrough 2020 Trials in Multiple Tumor Types and Data Update on the Company’s N-803 IL-15 Superagonist, which Recently Received Breakthrough Therapy Designation from the FDA    CULVER CITY, Calif., January 7, 2020  – 
View HTML
Toggle Summary NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein
World’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of both the NK and T-cells demonstrated complete response in second-line metastatic pancreatic cancer, confirmed by PET/CT scan.
View HTML
Toggle Summary Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference
Complete Responses Noted in Multiple Tumor Types (including Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer, Merkel Cell Cancer, Bladder Cancer, and Non-Hodgkin’s Lymphoma) when Natural Killer cells and T cells are activated simultaneously FDA Registrationfilings in Bladder,
View HTML
Toggle Summary NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells
Clinical trial for patients failing checkpoint therapy uses combination of first-in-class, cryopreserved, CD16 NK cells, ImmunityBio’s IL-15 superagonist and checkpoint inhibitor Avelumab EL SEGUNDO, Calif. --(BUSINESS WIRE)-- NantKwest, Inc. (Nasdaq: NK), a next-generation, clinical-stage
View HTML